Treating genetic disease at scale with tRNA, with Michelle W...
Michelle Werner, CEO of Alltrna, discusses her company’s approach of leveraging transfer RNA (tRNA) to shift the paradigm in genetic medicine.
Newsletters and Deep Dive digital magazine
Michelle Werner, CEO of Alltrna, discusses her company’s approach of leveraging transfer RNA (tRNA) to shift the paradigm in genetic medicine.
The co-founders of mRNA specialist BioNTech – husband and wife team Uğur Şahin and Özlem Türeci – have said they are leaving to set up a new company.
Bristol Myers Squibb now has positive phase 3 data under its belt for celmod mezigdomide, as it waits for an FDA verdict on lead drug iberdomide.
The FDA has issued additional guidance that aims to make it easier for drugmakers to bring biosimilars of patent-expired biologic drugs to market.
January and February this year weren't a story of a few dominant megadeals, but rather a dense constellation of cross‑disciplinary alliances.
Editor's Picks
Newsletters and Deep Dive
digital magazine